. 2012 Oct 19;24(1):23–57. doi: 10.1007/s00198-012-2074-y

Table 11.

Anti-fracture efficacy of the most frequently used treatments for postmenopausal osteoporosis when given with calcium and vitamin D, as derived from randomised controlled trials (updated from [2])

	Effect on vertebral fracture risk		Effect on non-vertebral fracture risk
	Osteoporosis	Established osteoporosis^a	Osteoporosis	Established osteoporosis^a
Alendronate	+	+	NA	+ (Including hip)
Risedronate	+	+	NA	+ (Including hip)
Ibandronate	NA	+	NA	+^b
Zoledronic acid	+	+	NA	+^c
HRT	+	+	+	+ (Including hip)
Raloxifene	+	+	NA	NA
Teriparatide and PTH	NA	+	NA	+^d
Strontium ranelate	+	+	+ (Including hip^b)	+ (Including hip^b)
Denosumab	+	+^c	+ (Including hip)	+^c

NA no evidence available, + effective drug

^aWomen with a prior vertebral fracture

^bIn subsets of patients only (post hoc analysis)

^cMixed group of patients with or without prevalent vertebral fractures

^dShown for teriparatide only